KyungDong Pharm Co., Ltd. will release the combination hypertension treatment drug “Valdipine Tablet” on October 1st. Valdipine tablets are a combination anti-hypertensive drug whose main ingredients are Amlodipine besylate of the CCB class and Valsartan of the ARB class. Valdipine tablets are the first CCB + ARB combination drug and are the same as the well-known Expo drug, forming an annual market worth 80 billion won. In particular, Amlodipine, a component of Valdipine tablets, is the ingredient with the largest market share among CCB-based preparations, and Valsartan is the ingredient with the largest market share among ARB-based preparations. As such, Valdipine tablets, which are released as a combination of ingredients with the highest prescription rate in each class, are expected to serve as a growth engine in the existing hypertension treatment market. In addition, as the recent paradigm of hypertension treatment has changed to the combination or combination administration of CCB and ARB, the potential growth potential is expected to be very large. Valdipine tablets are released in three strength combinations of Amlodipine and Valsartan, 5/80, 5/160, and 10/160mg, respectively, providing a wide range of choices for combination administration. KyungDong Pharm Co., Ltd., which has been a strong player in the circulatory system market, especially in the hypertension treatment market, is expected to launch Valdipine Tablet as a leader in the company's future growth.
☆ Product Information ☆
|
|
Valdipine tablets 5/80mg |
Valdipine tablets 5/160mg |
Valdipine Tablet 10/160mg |
|
Ingredient content |
Amlodipine besylate 5mg Valsartan 80mg |
Amlodipine besylate 5mg Valsartan 160mg |
Amlodipine besylate 10mg Valsartan 160mg |
|
Indications |
Essential hypertension whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy | ||
|
Dosage and usage |
The recommended dosage is 1 tablet once a day, taken with water regardless of meals. If possible, it is recommended to take it at the same time every day. It is recommended to adjust the dosage of each ingredient before administering this medicine, but if blood pressure is not controlled with monotherapy with each ingredient, you can consider switching to this medicine right away. | ||
|
Reimbursement Code |
648103300 |
648103280 |
648103290 |
※ For other details, please refer to the product manual.